IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 46216

t application of

SASAKI et al.

Serial No. 09/700,187

Filed: November 13, 2000

For:

LIGHT-REPRESSIBLE PROMOTERS

Group Art Unit: 1638

Examiner: Helmer, Georgia L.

RECEIVED

TECH CENTER 1600/2900

TRANSMITTAL OF RESPONSE

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Transmitted herewith is an Response in the above-captioned application. The fee has been calculated as shown below. (Small entity fees indicated in parentheses.)

			CLAIMS AS AMEND	JEU		
(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Claims Remaining After Amendment		Highest Number Previously Paid For	Extra Claims	Rate	Fee
Total Claims	36	-	36		18.00	\$0
(Small Entity)					(9.00)	
Independent claims	4	-	4		84.00	\$0
(Small Entity)					(42.00)	
Multiple Dependent	0	-	0	0	280.00	0
(Small Entity)					(140.00)	
Extension of Time	One Month		Two Months	Three Months		
Fee	\$110		\$410	\$930		\$0
(Small Entity)	(\$55)		(\$205)	(\$465)		0
Total						\$0

The above fees are believed to be correct. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0687 under the above Attorney Docket Number for which purpose this paper is submitted in duplicate.

Respectfully submitted,

February 27, 2003 Date:

Paul E. White, Jr.

Reg. No. 32,011 Tel. No. 202-261-1050 Fax No. 202-887-0336

Manelli Denison & Selter, PLLC 2000 M Street, N.W. Suite 700 Washington, D.C. 20036-3307 202.261.1000

A cation No.04 1700, 187

ICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING EOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

्रियात है। nucleotide and/क्षे amino acid sequence disclosure contained in this application does not comply with the requirements th a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s): 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). An Initial or substitute computer readable form (CRF) copy of the "Sequence Listing An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) or questions regarding compliance with these requirements, please contact: MAR 0 3 2003 or Rules Interpretation, call (703) 308-1123 TECH CENTER 1600/2900 or CRF submission help, call (703) 308-4212 or Patentin software help, call (703) 308-6856 ase, return a copy of this notice with your response DR. GEORGIA HELMER